Magnetic Group Signaling (MGS®) standardizes NMR systems and sample processing to ensure reproducible results on different NMR instruments.
Cancer is among the leading causes of death worldwide. Approximately 38 % of men and women will be diagnosed with cancer at some point during their lifetimes (based on 2013 – 2015 data1). Cancer can occur in any organ and in any cell type and the variability in clinical presentation makes early diagnosis difficult. Common cancers with established benefit of early diagnosis but for which there are no sensitive or specific tests are prostate, bladder and liver cancer1.
Expensive imaging procedures are routinely required in clinical practice for diagnosis or to monitor disease progression of these cancers. To date, there are no accurate biomarkers for either diagnosis or disease progression monitoring for prostate, bladder or liver cancer. Often the poor accuracy of existing cancer biomarkers confuses clinical decision making rather than assist in disease diagnosis or monitoring.
(in dev.) Numares currently focuses its research on prostate, bladder and hepatic cellular cancer. The objective is to find metabolite biomarker profiles indicating the presence of cancer which could be used in diagnostic screening.
More information on the AXINON® System:
Our oncology biomarker development pipeline and all future test applications will be available for the AXINON® System which produces high-quality, standardized NMR spectra based on Numares’ Magnetic Group Signaling (MGS®) technology.
The combination of MGS® technology with the AXINON® System allows for test-specific spectral analysis with highly-reproducible results. The test system is easy to use with one-step sample preparation with ready-to-use reagents requiring minimal operator interaction. The test system is fast and efficient with automation capabilities allowing short hands-on-time and high walk-away capability.
To date, more than 2 million tests have been performed worldwide based on Numares’ technology.